Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 122

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 122
---
 enhance the relevance of our risk assessments. We believe that the safety management systems implemented at each site, the hazard studies carried out and the risk management methods implemented, as well as our third-party property insurance policies covering any third-party physical damage, are consistent with legal requirements and the best practices in the industry, although no guarantee can be given that they will prevent accidents of various kinds. We have also designed a new Global Safety Culture program — “Leading Safety” — to help protect the health and safety of our employees, contractors and communities. It is based on five positive performance drivers: strengthen safety leadership; focus on key risks; increase managerial skills; improve safety barriers and the effectiveness of controls; and increase reports of unsafe acts & hazardous conditions. Environment Beyond healthcare, we have taken steps to address the environmental impacts of our products and activities and to help strengthen our resilience in the face of environmental changes. We have identified six major environmental challenges relating to our businesses: greenhouse gas emissions and climate disruption; eco-design; water; pharmaceuticals in the environment; waste; and biodiversity. We have been implementing environmental initiatives since 2010. More recently, we established the Planet Care program, which seeks to address environmental impacts across the value chain. We have also taken measures to seek to reduce our greenhouse gas emissions and pursue more sustainable water resource management, especially at sites which are under hydric stress, and have set both medium-term and long-term targets. See “Cautionary statement regarding forward-looking statements” and “Item 3.D. Risk Factors.”

| 52 | SANOFIFORM 20-F2024 |

| PART I                             |
| ITEM 4. Information on the Company |

C. Organizational Structure C.1. Significant Subsidiaries Sanofi is the holding company of a consolidated group consisting of almost 260 companies. The principal companies in the Sanofi group as of December 31, 2024 is provided in Note F. to our consolidated financial statements, included in Item 18. of this annual report. Since 2009, we have transformed Sanofi through numerous acquisitions and divestments, in particular the acquisitions of Genzyme in April 2011, Boehringer Ingelheim (BI) Consumer Healthcare in January 2017 (mainly through an asset purchase) , Bioverativ in March 2018, Ablynx in June 2018, Synthorx in January 2020, Principia in September 2020, Kymab in April 2021, Translate